Starpharma (ASX:SPL) and the Peter MacCallum Cancer Centre have been awarded a further federal government Innovation Connections grant to support research within the company's DEP oncology program.
Starpharma’s DEP dendrimer platform is designed to improve drug efficacy and reduce off-target toxicity with the goal of improving outcomes for cancer patients. Oncology therapeutic agents are commonly used in combination to achieve optimal impact on cancer cells. This $50,000 grant will be used to assess new and existing DEP candidates in combination with existing therapeutic agents.
According to Starpharma CEO, Dr Jackie Fairley, “Peter MacCallum Cancer Centre has been an outstanding long-time collaborator for Starpharma and we are delighted to continue our work with Dr Carleen Cullinane and her expert team in translational research. This work could generate important data aimed at improving treatment regimens and further enhances commercialisation opportunities for Starpharma’s DEP technology. This Federal Government funding helps to build critical partnerships between commercial enterprises and the research sector.”
Dr Carleen Cullinane, Co-Head of Peter Mac’s Translational Research Lab said, “We are enthusiastic to work with Starpharma to develop DEP dendrimer drug delivery combinations. The Innovation Connections grant program is supporting exciting innovative technology to have the greatest patient impact.”